Our Projects
TauRx Pharmaceuticals
Pioneering Alzheimer's Disease Treatment
TauRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing breakthrough treatments for Alzheimer's disease and other neurodegenerative disorders. Founded in 2002 and led by Professor Claude Wischik, TauRx has dedicated over two decades to tau protein research—a key mechanism underlying Alzheimer's disease progression. INVESTMENT THESIS Alzheimer's disease represents one of the world's greatest unmet medical needs, affecting over 55 million people worldwide. TauRx's novel approach targeting tau protein aggregation offers a differentiated therapeutic strategy with significant commercial potential. KEY MILESTONES - Completed Phase III clinical trials (LUCIDITY study) in 2022 - Secured $119 million in funding following positive Phase III results - Granted UK MHRA Innovation Passport in May 2022 - Total funding raised: $348+ million from institutional investors - Advancing regulatory submissions in UK, US, and Canada.
​
TauRx is a Singapore company. It has raised over US$ 1 Billion with 1600 shareholders
HEADQUARTERS
Aberdeen, United Kingdom | Singapore WEBSITE : www.taurx.com
QuantumTx Revolutionary Muscle Health Technology
QuantumTX, was founded in 2019 by NUS
Associate Professor Alfredo Franco-Obregón and Professor
Lee Chuen Neng.
​
Leveraging decades of research, they developed the Muscle
Magnetic Mitohormesis patented technology, which provides
users safe and gentle muscle activation and empowers them
to get fitter, healthier and enhances their capacity for exercise.
​
QuantumTx has developed MitoCharge™—a non-invasive magnetic mitohormesis system that activates muscle mitochondria to enhance recovery, rehabilitation, and healthy aging without physical exercise.
The technology originated from National University of Singapore research and has been validated for clinical and wellness applications.INVESTMENT THESISAs global populations age and healthcare costs rise, non-invasive technologies that improve muscle health and reduce rehabilitation time represent a high-growth opportunity. QuantumTx addresses markets spanning clinical rehabilitation, sports performance, and longevity.
​
HEADQUARTERS Singapore
WEBSITEwww.quantumtx.com | www.mitocharge.com
AWE SuperMeals
(Wholesome Savour) Clinically Validated Functional Nutrition
AWE SuperMeals represents the world's first clinically validated, nutrition-focused functional meals that deliver measurable health benefits. Developed over 16 years by founder Jason Fong, AWE combines advanced food science with nutritional optimization to create clean-label supermeals backed by clinical evidence. INVESTMENT THESIS The functional foods market is experiencing rapid growth as consumers demand science-backed nutrition solutions. AWE's clinical validation and proprietary food technology position it as a premium player in the health optimization segment. KEY DIFFERENTIATORS - First clinically proven nutritional functional meals - Improves health biomarkers within 10 days (clinically validated) - Proprietary food technology: toxin elimination & nutrient encapsulation - Clean Label approach: no artificial additives or preservatives - 16 years of R&D investment - 8+ days of preparation per meal batch INNOVATION AWE's hallmark processes encompass advanced food technology that eliminates toxins from raw ingredients, encapsulates nutrients, and ensures high bioavailability—significantly improving nutrient absorption and health outcomes.
FOCUS AREAS - Disease prevention through functional nutrition - Health biomarker optimization - Anti-inflammatory whole food formulations - Sustainable food production
​
HEADQUARTERS Singapore
WEBSITE www.awesupermeals.com